

# A Review on the Potential Therapeutic Profile of Carica papaya Leaf Extract in the Management of Dengue Fever

---

*- DR. PRADEEP B. E.*

*POST GRADUATE*


*DEPARTMENT OF PHARMACOLOGY, J.J.M.MEDICAL COLLEGE,*

*DAVANGERE*



# INTRODUCTION

---



- Acute viral infection
- Dengue viruses (DV): genus Flavivirus, family Flaviviridae
- Positive stranded encapsulated RNA virus
- 3 structural protein genes: C, M, E
- 7 NS protein genes



- 
- Aedes aegypti mosquito transmission
  - 1997 WHO classification of Dengue infection
    - Undifferentiated Fever
    - Dengue Fever (DF) and
    - Dengue Haemorrhagic Fever (DHF)
  - 2009 WHO classification,
    - Uncomplicated
    - Severe

# CLINICAL PRESENTATION



## ➤ Four main characteristic manifestations

- Continuous high fever lasting 2-7 days;
- Haemorrhagic tendency;
- Thrombocytopenia (platelet count  $<100 \times 10^9/L$ ); and
- Evidence of plasma leakage

## ➤ Incubation period: 3 to 14 days

➤ After the incubation period, the illness begins abruptly

➤ Patients with moderate to severe disease, 3 phases

- Febrile,

- Critical and

- Recovery

➤ **Individual risk factors:** secondary infection, age (young children) , ethnicity and possibly chronic diseases

➤ Associated problems

Days of illness


Temperature

Potential clinical issues

Laboratory changes

Serology and virology

Phases of illness




# Diagnosis

---

- Typically made clinically
- A probable diagnosis is based on the findings of fever plus any 2 of the characteristic features
- The earliest change detectable on laboratory investigations
- Peripheral vascular collapse in children
- Warning signs are an important aspect for early detection

# Laboratory tests

- Diagnosis confirmed by microbiological laboratory testing
  - Virus isolation in cell cultures
  - Nucleic acid detection by PCR
  - Viral antigen detection (such as for NS1) or
    - Specific antibodies (serology)
- All tests may be negative in the early stages of the disease
- PCR and viral antigen detection are more accurate in the first seven days



*Graph of when laboratory tests for dengue fever become positive. Day zero refers to the start of symptoms, 1st refers to in those with a primary infection, and 2nd refers to in those with a secondary infection.<sup>[9]</sup>*

# Problem Statement

---

- Risk population: Over 2.5 billion people – over 40% of the world's population
- WHO estimation,
  - ✓ 50–100 million dengue infections and half a million DHF worldwide every year
  - ✓ Average case fatality rate  $\approx 5\%$
- Endemic in over 125 countries
- The exact extent of the problem not known



# *Currently available treatment modalities*

---

- Treatment depends on the symptoms & severity
- IV fluids- titrated
- Blood transfusion initiated early in patients presenting with unstable vital signs
- Packed red blood cells or whole blood recommended
- Thrombocytopenia not addressed till it gets lowered down to levels less than 20000 / $\mu$ l
- Reduction of mortality due to DHF from 20% to less than 1%
- Corticosteroid


- 
- TPO agonists and mimetics like **Eltrombopag and Romiplastim**
  - Dengue vaccine – under trial
  - Alternatively other options need to be explored
  - Considerations for alternate therapies
  - **Traditional medicine**

# *Carica papaya (CP)*

---

- Genus *Carica* of the plant family Caricaceae
- Cosmopolitan in distribution
- Leaves of Papaw are rich in anthraquinone and alkaloids like carpaine, a glucoside named carposide, flavonols and vitamins C and E
- TJ O'Hare and DJ Williams - 'Papaya As A Medicinal Plant'

anthelmintic activity, wound healing, antifertility properties, antifungal activity, antimalarial activity, antimicrobial activity, antiviral activity (dengue fever), anticancer and chemoprotection, anti-amoebic activity, diabetes and anti-hypertension



- 
- Literature search: consistent results
  - **\*NADEEM SHEIKH, NEELAM YOUNAS & TASLEEM AKHTAR** on “**Effect of *Carica papaya* leaf formulation on Haematology and Serology of normal rat**” illustrated an exact mechanism of Thrombocyte formation
  - Consumption for longer period: hepatotoxicity and risk for cardiovascular disease
  - Probable action of Vitamin C
  - In a clinical trials, 1100 mg TID of *Carica Papaya* leaf extract tablet (Caripill) for 5 days – significant increase in platelet count



- 
- Sathasivam et al. (2009) – mice
  - Ahmad et al. (2011), Hettige S. (2008), Yunita F (2012) and Soobitha Subenthiran (2013) – clinical trials
  - NADEEM SHEIKH et al. **“Effect of *Carica papaya* leaf formulation on Haematology and Serology of normal rat”** - ↑ mean platelet count, MCH, MCV
  - **“Identification of Secondary Metabolites Present in *Carica Papaya* L. Leaf Extract Found in Northern India by HPTLC & Other Test Procedures, its Significance and Role in Curing Dengue/DHF Disease”** by Dinesh Kumar et al. - physico-chemical and phytochemical evaluation

- 
- TLC fingerprinting profile of different extracts → Secondary metabolites → Bioactive components separated from the co extractives → Secondary metabolites
  - Flavonoids like quercetin, alkaloids like piperine, glycosides, saponins, tannins, terpenoids like triterpenoids, phytosterols and phenolics
  - None any single ingredient/constituent or factor found responsible

# Significance

---

- Better & viable option in fever associated with thrombocytopenia
- Palatable and appropriately formulated
- Fewer side effects
- Decreases the cost of hospitalization
- Cost effective
- More affordable and accessible
- Averting the mortalities



- 
- International Anti dengue day - June 15<sup>th</sup>
  - Intention to meet the achievable goals





# CONCLUSION

---

- Serious public health problem worldwide
- Validation of traditional claims
- Discrepancy regarding its safety profile
- Cost effective - positive influence on the national economy
- Need for further studies on a large scale
- Considerations for nutraceutical and its potential as pharmaceutical



# References

---

- ❖ Nivedita Gupta *et al.* — Dengue in India; Centenary Review Article; *Indian J Med Res.* 136, p 373-390, September 2012.
- ❖ *Dengue haemorrhagic fever: diagnosis, treatment, prevention and control* (PDF) (2nd ed.). Geneva: World Health Organization. pp. 12–23. ISBN 92-4-154500-3.
- ❖ WHO (2009), pp. 10–11.
- ❖ WHO. 2. Dengue: Guidelines for diagnosis, treatment, prevention, and control in sub-Saharan Africa and 13 countries in South America. Geneva: World Health Organization; 2009, 2012.

- 
- ❖ Esler D. — Dengue - Clinical and public health ramifications. *Aust Fam Physician*. 38:876–879, 2009. (PubMed).
  - ❖ Halstead S. B. — The pathogenesis of dengue: Molecular Epidemiology in Infections Disease. *Am J Epidemiol*. 114(5): 632-648, 1981.
  - ❖ Ferreira G.L. — Global dengue epidemiology trends. *Rev Inst Med Trop Sao Paulo*.54 (Suppl 18):S5–6, 2012. (PubMed)
  - ❖ Selisko B, Dutartre H, Guillemot JC. Comparative mechanistic studies of de novo RNA synthesis by flavivirus RNA dependent RNA polymerases. *Virology* 2006; 351(1): 145-148.
  - ❖ "Re: Papaya leaves for speedy rise of platelet count in Dengue". *BMJ*. Retrieved 2013-06-15.

# Good Health Needs Good Care

---

